Jio has continued its strong subscriber growth trend with net addition during the quarter of 28.7 million (as against 26.5 million in the previous quarter). This is the highest net addition in any quarter since the launch of commercial services.

The company stated that clinical research business will hit top-line from the last quarter of the ongoing financial year. The company is expecting to add a revenue of Rs. 250 crores in the fifth year through clinical research services.

Thyrocare Technologies gained over 7.5 per cent in the early morning trade on Monday as the company announced plans to consider buyback of shares.

The net interest income for the quarter increased by 28 per cent yoy and 9.5 per cent qoq to Rs. 4,381 crore in Q1FY19 vs Rs. 3,405 crore in the same period the previous year. The interest income for the quarter rose by 10.3 per cent yoy to Rs. 11,639 crore in Q1FY19.

Aurobindo Pharma has received the final approval from the US Food and Drug Administration for Bivalirudin Injection indicated for the use as an anticoagulant in patients. The product will be launched in September 2018. With respect to the news, the shares of Aurobindo soared 2 per cent.

The markets on July 30, 2018 opened gap up. BSE Sensex is trading at 37,407.49, up by 70.64 points and the Nifty is trading at 11,290.45, up by 12.10 points.

Wockhardt Limited has set-up its first facility in the Middle East for manufacturing of NCEs (New Chemical Entities). It will cater to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.

ICICI Bank posted a net loss in Q1FY19 due to higher provisions in the quarter. However, the bank also witnessed an improvement in asset quality.

The USFDA has accorded twin approvals to the company's bulk drug facilities in Baddi and Masulkhana, in Himachal Pradesh for export to the US market. The stock spiked up by more than 10 per cent on Monday.